Real-time ESG Scores

Alexion Pharmaceuticals, Inc

Alexion Pharmaceuticals, Inc is part of the Pharmaceuticals, Biotechnology & Life Sciences sector. The company has a ESG Pulse of 0.94 which is calculated using alternative data outside of company disclosure to provide an 'outside-in' view on company ESG performance.

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

ESG Pulse

ESG Pulse is ranked on a scale of -1 (negative) to +1 (good). This is the average sentiment of all items that have been classified as material ESG'
Updated on:
2022-04-12

Historical ESG Pulse

View historical company ESG pulse and compare against industry, overlay stock prices or view vs peers.

Materiality

View company ESG performance broken down by the 26 SASB topics.

Traditional ESG data doesn't give you the full picture

Old style esg data
The old way
Reliant on company disclosure and analysts
Traditional providers such as MSCI and Sustainalytics rely on company disclosure - which happens infrequently. They employ armies of analysts to gather this data.
  • ESG data and scores are stale (every 6-12 months)
  • Low amount company coverage
  • ESG data is extremely expensive
  • ESG data is not always transparent/objective
Real time esg score in chart
The new way
Dynamic, real-time ESG data
Alternative data such as news, media, job postings, social media and others - allow us to extract signals from the 'outside-in' using AI and fully automated approaches.
  • A check mark
    Real-time ESG data
  • A check mark
    Unlimited coverage of public/private companies
  • A check mark
    Affordable software for analysis
  • A check mark
    Explainable, transparent ESG
start Your 7-day Free trial